Mary Kay Inc. Earns Several Awards for Work in Business, COVID-19 Response and Sustainability Efforts
11.8.2021 16:03:00 EEST | Business Wire | Press release
In 2021, Mary Kay Inc. continued its decades-long commitment to enriching the lives of women around the globe, manufacturing irresistible products and building healthier, more sustainable communities even in response to COVID-19. In recognition of Mary Kay’s achievements in the last six months, the brand has taken home several coveted awards in the business, corporate citizenship, and leadership categories from various prestigious organizations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210811005163/en/
Mary Kay was named a Silver Globee® Winner in 3 categories at the 13th Annual 2021 Golden Bridge Business and Innovation Awards. (Graphic: Mary Kay Inc.)
The awards, which range from recognition of the brand’s COVID-19 response to accolades for a Mary Kay-produced documentary on the Gulf of Mexico’s preservation efforts, highlight the company’s unwavering business values and its dedication to the principles defined by the brand’s legendary founder, Mary Kay Ash.
Latest awards include:
COVID-19 Response Awards
-
Silver Globee® Winner – 13th Annual 2021
Golden Bridge Business and Innovation Awards
- Team of the Year During COVID-19 (Hand Sanitizer Distribution Team)
- Company Response of the Year (Mary Kay Inc.)
- Best Product To Combat and Reduce the Impact of COVID-19 (Mary Kay Hand Sanitizer)
-
Gold Globee® Winner – 13th Annual 2021
Golden Bridge Business and Innovation Awards
- Best Non-Profit Response Helping Local Communities and the World During COVID-19 (The Mary Kay FoundationSM)
-
Silver Globee® Winner – 6th Annual 2021 American Best in Business Awards
- Team of the Year During COVID-19 (Hand Sanitizer Distribution Team)
- Company Response of the Year (Mary Kay Inc.)
- Best Product to Combat and Reduce the Impact of COVID-19 (Mary Kay Hand Sanitizer)
-
Gold Globee® Winner – 6th Annual 2021 American Best in Business Awards
- Best Non-Profit Response Helping Local Communities and the World During COVID-19 (The Mary Kay FoundationSM)
Company Awards
- America's Best Mid-Sized Employers 2021 – Forbes
- “Power of Woman” Award, Mary Kay Ukraine, joint project with Marie Claire - X-RAY Marketing Awards
- The Best Employer 2021, Mary Kay Poland – The Financial Magazine
- “Direct Sales Cosmetic Company Number One Award,” Mary Kay Belarus – “Number One” Annual National Awards
Sustainability Awards
Guardians of the Gulf, an eye-opening documentary that explores the tumultuous relationship between the Gulf of Mexico and the conservationists determined to protect it, has received various awards. Mary Kay Inc., serving as executive producer, with Media One in partnership with The Nature Conservancy, visited the coasts of Texas, Alabama and Mexico to shed light on the often-untold stories of Gulf preservation.
- Silver: Non-Broadcast General-Nature/Wildlife – Telly Awards
- Bronze: Non-Broadcast General-Documentary – Telly Awards
- Best Special Focus Documentary Finalist – LA Femme International Film Festival
- World Remi Award – Worldfest Houston International Film Festival
Leadership Recognition
- “67 Powerful Black Women CEOs And Executives In Corporate America,” Julia Simon, Chief Legal Officer and Corporate Secretary / Sheryl Adkins-Green, Chief Marketing Officer – Business Insider
- “TOP Women CEOs in Ukraine” in Women’s Leadership in the Corporate Sector and Business rating - Viktoriia Zoria-Iatsenko, General Manager, Mary Kay Ukraine – WoMo (The Portal for Working Women)
- “50 Most Valuable Women in Poland,” Ewa Kudlińska-Pyrz, General Manager, Mary Kay Poland – The Financial Magazine
- “The Top 100 Women Leaders In Consumer Products Of 2021,” Allyson Sellers, Vice President of Sales, Mary Kay U.S. – Women We Admire
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company nearly 60 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005163/en/
Contact information
Mary Kay Inc. Corporate Communications
Marykay.com/newsroom
(+1) 972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
